Advanced native kidney renal cell carcinoma in renal transplant recipients: role of sirolimus as dual anti-cancer and anti-rejection agent

Muhammad M. Javaid; Simon Chowdhury; Alastair Henderson; Jonathon Olsburgh

doi:10.5414/CN107107

Advanced native kidney renal cell carcinoma in renal transplant recipients: role of sirolimus as dual anti-cancer and anti-rejection agent

Muhammad M. Javaid^*, Simon Chowdhury, Alastair Henderson, Jonathon Olsburgh

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

The incidence of native kidney renal cell carcinoma (RCC) in renal transplant recipients is 15 times higher than the general population. These tumors are often found incidentally when imaging is performed for another indication. At that stage tumors are usually small and asymptomatic but it is possible that they may escape detection until a more advanced stage. Early stage RCC can be treated with radical nephrectomy but the treatment of advanced RCC may be more complicated and is associated with a poorer prognosis. RCC in context of renal transplant presents a special therapeutic challenge; balancing treatment of a potentially lethal malignancy in a redundant organ whilst maintaining good allograft function. We describe 2 cases of advanced renal cell carcinoma of native kidneys in renal transplant recipients and present our experience with sirolimus as a dual immunosuppressive and anti-tumor agent.

Original language	English
Pages (from-to)	154-160
Number of pages	7
Journal	Clinical Nephrology
Volume	79
Issue number	2
DOIs	https://doi.org/10.5414/CN107107
Publication status	Published - Feb 2013

Keywords

renal cell carcinoma
malignancy
renal transplantation
native kidney
sirolimus
CALCINEURIN INHIBITORS
CANCER
MALIGNANCIES
TRIAL

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.5414/CN107107

Cite this

@article{efc329fa0840439fa5fa6dc9d8e31c63,

title = "Advanced native kidney renal cell carcinoma in renal transplant recipients: role of sirolimus as dual anti-cancer and anti-rejection agent",

abstract = "The incidence of native kidney renal cell carcinoma (RCC) in renal transplant recipients is 15 times higher than the general population. These tumors are often found incidentally when imaging is performed for another indication. At that stage tumors are usually small and asymptomatic but it is possible that they may escape detection until a more advanced stage. Early stage RCC can be treated with radical nephrectomy but the treatment of advanced RCC may be more complicated and is associated with a poorer prognosis. RCC in context of renal transplant presents a special therapeutic challenge; balancing treatment of a potentially lethal malignancy in a redundant organ whilst maintaining good allograft function. We describe 2 cases of advanced renal cell carcinoma of native kidneys in renal transplant recipients and present our experience with sirolimus as a dual immunosuppressive and anti-tumor agent.",

keywords = "renal cell carcinoma, malignancy, renal transplantation, native kidney, sirolimus, CALCINEURIN INHIBITORS, CANCER, MALIGNANCIES, TRIAL",

author = "Javaid, {Muhammad M.} and Simon Chowdhury and Alastair Henderson and Jonathon Olsburgh",

year = "2013",

month = feb,

doi = "10.5414/CN107107",

language = "English",

volume = "79",

pages = "154--160",

journal = "Clinical Nephrology",

issn = "0301-0430",

publisher = "Dustri-Verlag Dr. Karl Feistle",

number = "2",

}

TY - JOUR

T1 - Advanced native kidney renal cell carcinoma in renal transplant recipients

T2 - role of sirolimus as dual anti-cancer and anti-rejection agent

AU - Javaid, Muhammad M.

AU - Chowdhury, Simon

AU - Henderson, Alastair

AU - Olsburgh, Jonathon

PY - 2013/2

Y1 - 2013/2

N2 - The incidence of native kidney renal cell carcinoma (RCC) in renal transplant recipients is 15 times higher than the general population. These tumors are often found incidentally when imaging is performed for another indication. At that stage tumors are usually small and asymptomatic but it is possible that they may escape detection until a more advanced stage. Early stage RCC can be treated with radical nephrectomy but the treatment of advanced RCC may be more complicated and is associated with a poorer prognosis. RCC in context of renal transplant presents a special therapeutic challenge; balancing treatment of a potentially lethal malignancy in a redundant organ whilst maintaining good allograft function. We describe 2 cases of advanced renal cell carcinoma of native kidneys in renal transplant recipients and present our experience with sirolimus as a dual immunosuppressive and anti-tumor agent.

AB - The incidence of native kidney renal cell carcinoma (RCC) in renal transplant recipients is 15 times higher than the general population. These tumors are often found incidentally when imaging is performed for another indication. At that stage tumors are usually small and asymptomatic but it is possible that they may escape detection until a more advanced stage. Early stage RCC can be treated with radical nephrectomy but the treatment of advanced RCC may be more complicated and is associated with a poorer prognosis. RCC in context of renal transplant presents a special therapeutic challenge; balancing treatment of a potentially lethal malignancy in a redundant organ whilst maintaining good allograft function. We describe 2 cases of advanced renal cell carcinoma of native kidneys in renal transplant recipients and present our experience with sirolimus as a dual immunosuppressive and anti-tumor agent.

KW - renal cell carcinoma

KW - malignancy

KW - renal transplantation

KW - native kidney

KW - sirolimus

KW - CALCINEURIN INHIBITORS

KW - CANCER

KW - MALIGNANCIES

KW - TRIAL

U2 - 10.5414/CN107107

DO - 10.5414/CN107107

M3 - Article

SN - 0301-0430

VL - 79

SP - 154

EP - 160

JO - Clinical Nephrology

JF - Clinical Nephrology

IS - 2

ER -

Advanced native kidney renal cell carcinoma in renal transplant recipients: role of sirolimus as dual anti-cancer and anti-rejection agent

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this